PHOENIX Trial of AMX0035 did not meet endpoints
March 08, 2024
Amylyx Pharmaceuticals has announced that the PHOENIX Phase 3 clinical trial of AMX0035 did not meet its primary or secondary endpoints. The results from the 48-week study, which involved participants from the United States of America and Europe, showed no…
Continue reading